Last reviewed · How we verify
NCT03208361: PENIPNEUMO
Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
Phase 3 trial testing Penicillin V in Community-acquired Pneumonia (CAP) in 43 participants. Terminated before completion.
29 March 2016
Quick facts
| Lead sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 5 November 2013 |
| Primary completion | 29 March 2016 |
| Estimated completion | 21 April 2016 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Penicillin V — full drug profile →
- Amoxicillin (amoxicillin) — full drug profile →
Conditions studied
- Community-acquired Pneumonia (CAP) — all drugs for Community-acquired Pneumonia (CAP) →
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — full company profile →
Who can join
Adults 18 to 75, any sex, with Community-acquired Pneumonia (CAP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate wether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-sever community-acquired pneumonia (CAP).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO-defined non-severe pneumonia and wheeze.
Lassi ZS, Padhani ZA, Das JK, Salam RA, et al · · 2021 · cited 8× · PMID 33469915 · DOI 10.1002/14651858.cd009576.pub3
Verify or expand the search:
- PubMed search for NCT03208361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina trials
Trials by the same sponsor.
- NCT07441759 — throMboembolic Risk Associated To High atrIal Fibrillation riSk · not yet recruiting
- NCT07132632 — Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults · NA · not yet recruiting
- NCT07373119 — Improving Frailty in Patients With Stable Ischemic Heart Disease · NA · enrolling by invitation
- NCT06581367 — Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care · Phase 4 · not yet recruiting
- NCT06988904 — ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03208361 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Last refreshed: 5 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03208361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing